ENA0000GenomicsFondazione IRCCS Istituto Nazionale dei Tumorihttps://www.ebi.ac.uk/ena/browser/view/PRJNA213907Homo sapiensWe treated the papillary thyroid carcinoma-derived cell line TPC1 with the RTK inhibitor RPI-1 to obtain a thyroid carcinoma cell model. The RET tyrosine kinase is a target of the inhibitor. Gene expression changes were evaluated comparing cells treated with the inhibitor for 24 hours versus cells treated with DMSO for 24 hours. Overall design: Biological triplicates for RPI-1 and DMSO treated cells were generated by independent treatments and total RNA extractions.ENAinhibitors, Profiling, Transcriptome, FATTY ACID OXYGENATION UPREGULATED 2, T5L23.5, Monitorings, Cell Lines, Gene, inhibitor, mKIAA1169, two-pore channel 1, Cell, Gene Expression Profilings, Gene Expression, Differential Display, Transcript Expression Analysis, transcription profiling, mRNA Differential Displays, Transcript Expression Analyses, Gene Expression Pattern Analysis, FOU2, Gene Expression Monitorings, Line, Analysis, Profilings, mRNA Differential Display, gene expression profiling, Lines, DmTpc1, Gene Expression Monitoring, Transcriptome Profiling, Analyses, mRNA, Transcriptome Profilings, ATTPC1, DmelCG6608, 5730403B01Rik, inhibiteur, Transcriptomics, ATCCH1, Differential Displays, Transcript Expression, Transcriptome Analysis, Transcriptome Analyses, Monitoring, Gene Expression Analysis, RPI., Gene Expression Analyses, inhibidor, Tpc1, TPC1, Expression Analysis, CALCIUM CHANNEL 1, Expression Analyses, CG6608human being, human., man0.00.00.00.00.00falseHomo sapiensGene expression profiling in TPC1 cell line treated with the RTK inhibitor RPI-12022-05-122014-06-30PRJNA213907GSE49414248103369606